 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139957] OF DEFINITIONS  ..................................................................................................................... 6  
PROTOCOL APPROVAL PAGE  ...................................................................................................... 7  
STATEMENT OF COMPLIANCE .................................................................................................... 8  
PROTOCOL SUMMARY  ................................................................................................................... 9  
SCHEMATIC OF STUDY DESIGN ................................................................................................ 11  
1 KEY ROLES  ........................................................................................................................... 11  
1.1 AUTHORIZED REPRESENTATIVE (SIGNATORY) / RESPONSIBLE PARTY  ........ 11 
1.2 STUDY ORGANIZATION  .................................................................................................... 11 
2 INTRODUCTION  .................................................................................................................. 11  
2.1 BACKGROUND INFORMATI ON ...................................................................................... 11 
2.2 RATIONALE  .......................................................................................................................... 12 
2.3 POTENTIAL RISKS AND BENEFITS  ............................................................................... 15  
2.3.1  KNOWN POTENTIAL RISK S ................................................................................................ 15 
2.3.2  KNOWN POTENTIAL BENE FITS  .........................................................................................  15 
3 OBJECTIVES AND PURPO SE ........................................................................................... 15  
4 STUDY DESIGN AND ENDPOINTS  .................................................................................. 16  
4.1 DESCRIPTION OF THE STUDY DESIGN  ........................................................................ 16 
4.2 STUDY ENDPOINTS  ............................................................................................................ 16 
4.2.1  PRIMARY ENDPOINTS  .........................................................................................................  16 
4.2.2  SECONDARY ENDPOINTS  ...................................................................................................  17 
4.2.3  EXPLORATORY ENDPOINT S .............................................................................................. 17 
5 STUDY ENROLLMENT AND WITHDRAWAL  .............................................................. 17  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139958] WITHDRAWAL O R TERMINATION  ............................................................ 19 
5.4.1  REASONS FOR WITHDRAWAL OR TERMINATION  ........................................................ 19 
5.4.2  HANDLING OF PARTICPANT WITHDRAWALS OR TE RMINATION  ............................  20 
5.4 PREMATURE TERMINATION OR SUSPENSION OF S TUDY  .................................... 20 
6 STUDY AGENT  ..................................................................................................................... 20  
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  ..................................................... [ADDRESS_139959] STORAGE AND STABILITY ..............................................................................  21 
6.1.4  PREPARATION  .......................................................................................................................  21 
6.1.5  DOSING AND ADMINISTR ATION  ......................................................................................  21 
6.1.6 ROUTE OF ADMINISTRATION ............................................................................................  22 
6.1.7  DOSING SCHEDULE ..............................................................................................................  22 
6.1.8  DURATION OF THERAPY  ....................................................................................................  22 
6.2 STUDY AGENT ACCOUNTA BILITY ................................................................................ 22 
7 STUDY PROCEDURES AND SCHEDULE  ....................................................................... 23  
7.1 STUDY PROCEDURES/EVALUATIONS  .......................................................................... 23 
7.1.1  STUDY SPECIFIC PROCE DURES  ........................................................................................  23 
7.2 LABORATORY PROCEDURE S/EVALUATIONS  ........................................................... 28 
7.2.1  CLINICAL LABORATORY EVALUATIONS .......................................................................  28 
7.2.2  OTHER ASSAYS OR PROC EDURES ....................................................................................  28 
7.2.3  SPECIMEN PREPARATION , HANDLING, STORAGE,  AND SHIPPI[INVESTIGATOR_1645]  ..........................  29 
7.3 STUDY SCHEDULE  .............................................................................................................. 29 
7.3.1  SCREENING  ............................................................................................................................  29 
7.3.2  BASELINE  ...............................................................................................................................  30 
7.3.3  RANDOMIZATION  .................................................................................................................  30 
7.3.4  TREATMENT ..........................................................................................................................  30 
7.3.5  FOLLOW -UP VISITS  ..............................................................................................................  31 
7.3.6  FINAL STUDY VISIT  .............................................................................................................  31 
7.3.7  EARLY TERMINATION VISIT  .............................................................................................. 32 
7.3.8  SCHEDULE OF EVENTS TABLE  ..........................................................................................  32 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  ................ 32 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  ...................... 32 
8 ASSESSMENT OF SAFETY  ................................................................................................ 32  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 3 of 69 
8.1 SPECIFICATION OF SAF ETY PARAMETERS  .............................................................. 32 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  .........................................................................  32 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) ...................................................... 33 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ................................................................ 34 
8.2.1  SEVERITY OF EVENT  ...........................................................................................................  34 
8.2.2  RELA TIONSHIP TO STUDY AGENT ...................................................................................  35 
8.2.3  EXPECTEDNESS ....................................................................................................................  35 
8.3 TIME PERIOD/FREQUENC Y FOR EVENT ASSESSME NT/FOLLOW -UP ................ [ADDRESS_139960]  .....................................................................  38 
8.4.4  REPORTING OF PREGNAN CY .............................................................................................  38 
8.5 STUDY HALTING RULES  ................................................................................................... 39 
8.6 SAFETY OVERSIGHT  ......................................................................................................... 39 
9 CLINICAL MONITORING  ................................................................................................. 40  
10 STATISTICAL CONSIDER ATIONS  .................................................................................. 40  
10.1  STATISTICAL DESIGN MODEL AND ANALYTICAL PLANS  .................................... 40 
10.2  STATISTICAL HYPOTHES ES ........................................................................................... 40 
10.3  ANALYSIS DATASETS  ........................................................................................................ 40 
10.4  DESCRIPTION OF STATISTICAL METHODS  ............................................................... 41 
10.4.1  GENERAL APPROACH  ..........................................................................................................  41 
10.4.2  ANALYSIS OF THE PRIM ARY ENDPOINT  ........................................................................  41 
10.4.3  ANALYSIS OF THE SECONDARY EFFICACY ENDPOINTS ............................................ 41 
10.4.4  ANALYSIS OF THE SECO NDARY SAFETY ENDPOIN TS ................................................  41 
10.4.5  ADHERENCE AND RETENT ION ANALYSES  ....................................................................  42 
10.4.6  BASELINE DESCRIPTIVE  STATISTICS  ..............................................................................  42 
10.4.7  PLANNED INTERIM ANAL YSES .........................................................................................  42 
10.4.8  ADDITIONAL SUBGROUP ANALYSES ..............................................................................  42 
10.4.9  MULTIPLE COMPARISON/ MULTIPLICITY .......................................................................  42 
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  .......................................................  42 
10.4.11  EXPLORATORY ANALYSES  .............................................................................................. 42 
10.5  SAMPLE SIZE  ........................................................................................................................ 43 
10.6  MEASURES TO MINIMIZE  BIAS  ...................................................................................... 43 
10.6.1 ENROLLMENT/RANDOMIZA TION/MASKING PROCEDU RES ......................................  43 
10.6.2  EVALUATION OF SUCCES S OF BLINDING  ......................................................................  43 
10.6.3  BREAKING THE STUDY B LIND/SUBJECT CODE  ............................................................ 43 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 4 of 69 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ............ 44  
12 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ........................................................... [ADDRESS_139961]  ................................................................................. 44 
12.3  INFORMED CONSENT PRO CESS .................................................................................... 45 
12.3.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS  ............................  [ADDRESS_139962] POLICY  .................... 50  
15 SCHEDULE OF EVENTS  .................................................................................................... 51  
15.1  SCHEDULE OF EVENTS T ABLE ...................................................................................... 51 
16 REFERENCES  ....................................................................................................................... 53  
16.1  PUBLISHED REFERENCES  ............................................................................................... 53 
16.2  UNPUBLISHED REFERENC ES .......................................................................................... 55 
17 APPENDICES  ........................................................................................................................ 56  
18 REVISION HISTORY ........................................................................................................... 65  
18.1  SUMMARY OF CHANGES  .................................................................................................. 65 
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139963] OF ABBREVIATIONS  
AD Alzheimer’s Disease  
ADCS -ADL -
Severe  Alzheimer’s Disease Cooperative Study  Group Activities of Daily Living 
Inventory  for Severe Alzheimer’s Disease  
ADCS -CGIC  Alzheimer’s Disease Cooperative Study – Clinical Global Impression of 
Change  Caregiver Input  
ADL  Activities of daily living  
AE Adverse Event  
ApoE  Apolipoprotein E  
CFR  Code of Federal Regulations  
CMP  Clinical Monitoring Plan  
CRF  Case Report Form  
CSF Cerebrospi[INVESTIGATOR_124478] E6 R2  International Conference on Harmonization Guidance for Industry, Good 
Clinical Practice: Consolidated Guidance, Revision [ADDRESS_139964]  
ITT Intent -To-Treat  
IV Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MHIS  Modified Hachinski Ischemia Scale  
MMSE  Mini -Mental State Examination  
NIA-AA National Institute on Aging  – Alzheimer’s Association  
NODscid  Non-obese diabetic severe combined immunodeficiency  
NPI [INVESTIGATOR_124479]-NH Neuropsychiatric Inventory  Nursing Home Version  
NSG  NODscid Gamma  
PT Preferred Term  
SAE  Serious Adverse Event  
SAP  Statistical Analytical Plan  
SIB Severe Impairment Battery  
SOC  System Organ Class  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
UPCR  Urine Protein -to-Creatinine Ratio  
US [LOCATION_002]  
   
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139965] /placebo .  The Infusion Nurse ensures 
that the investigational product  (GRF6019)/placebo is allocated appropriately and 
administered at the correct infusion rate .  The Infusion Nurse is also responsible 
for ensuring that appropriate blinding techniques are used to prevent inadvertent 
unblinding of study staff and subjects during and immediately following the 
Infusion Period.   
Infusion Period  The period during which GRF6019/placebo is infused.  
Outcomes Assessor  The blinded study personnel , qualified by [CONTACT_3903] , responsible 
for observing study subjects during the infusion of the investigational product /placebo  and collecting and/or managing adver se events (AEs) that occur 
before, during, and after the infusion period.  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 7 of 69 
PROTOCOL APPROVAL PAGE 
   
Study Title:  A Randomized, Double -Blind, Placebo -Controlled Study  to Assess 
the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects 
with Severe Alzheimer’s Disease  
Protocol Number:  ALK6019 -202 
Version/Date:  V3.0_10JUL2019  
Sponsor Name [CONTACT_13311]:  
 Alkahest, Inc.  
[ADDRESS_139966] relevant version, and applicable legal and regulatory requirements.  
 
 
   
Approved by:  
  
   
  
 
[INVESTIGATOR_12174] (print)   Signature   [CONTACT_124553]: D8B978FB-444E-4AA5-9E13-1855E6E7A705
10-Jul-2019

 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 8 of 69 
  
STATEMENT  OF COMPLIANCE  
 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled Study to Assess the Safety 
and Tolerability of Pulsed GRF6019 Infusions in Subjects with Severe 
Alzheimer’s Disease  
Protocol Number:  ALK6019 -202  
Version/Date : V3.0_10JUL2019   
 
By [CONTACT_27616], I:  
• Confirm that my staff and I have carefully read and understand this protocol or protocol amendment 
and are thoroughly familiar with the appropriate use of the investigational agent described herein.  
• Agree to comply with the conduct and terms of the study specified herein and with any other study 
conduct procedures provided by [CONTACT_1034], Alkahest, Inc., or their designee  
• Agree to assume responsibility for the proper conduct of the study at this site, including complying with current relevant versions of th e US Food and Drug Administration (FDA) regulations, the 
International Conference on Harmonization (ICH) GCP guidelines, the Declaration of Helsinki, and all 
applicable rules, regulations, and federal, state, and local laws relating to the conduct of clinical studies 
and the protection of human subjects.  
• Agree not to implement deviations from or changes to the protocol or protocol amendments without 
agreement from the Sponsor and prior submission to and written approval (where required) from the 
Institutional Review Board (IRB), except when necessary to eliminate an immediate hazard to the subjects, or for administrative aspects of the study (where permitted by [CONTACT_124519]).  
• Agree to onsite monitoring of all source documents by A lkahest, Inc. or designee and to onsite 
inspection of source documents by [CONTACT_4708], including but not limited to the FDA, local governing regulatory bodies, and IRB inspectors.  
 
 
 
   
Investigator's Signature   [CONTACT_124554]6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 9 of 69 
PROTOCOL SUMMARY  
  
Title:  A Randomized, Double -Blind, Placebo -Controlled Study to Assess the 
Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects with 
Severe Alzheimer’s Disease  
 
Précis:  This is a randomized, double -blind, placebo -controlled study to assess the 
safety and tolerability of GRF6019, a  human plasma protein fraction, 
administered by [CONTACT_33980] (IV) infusion in  subjects with severe 
Alzheimer’s disease (AD).  
 The study consists of approximately 20 subjects who will be randomized  in 
a 2:1 ratio  to active GRF6019 or placebo.  Treatment groups will be 
stratified by [CONTACT_4321].  S ubjects will receive one infusion per day of active or 
placebo treatment for 5 consecutive days during W eek 1  of the study.   The 
total study duration for the subjects will be approximately  9 weeks.  
 The infusion procedure  of active and placebo agents will be identical to 
maintain blinding.  The following measures will be taken to ensure 
adequate allocation concealment during infusions: blinding of subjects,  
study coordinators, physicians, and cognitive test administrators to treatment allocation ; use of blinded Outcomes Assessors and unblinded 
Infusion Nurses; and measures to block view of the  and other 
infusion equipment/supplies  throughout the infusion.  
 
All subjects will undergo a screening visit, baseline visit, treatment period, 
follow -up visits , and an -end-of-study/early -termination visit.  Safety and 
tolerability assessments will occur at every visit.  Cognitive  and other  
assessments will be performed at Baseline and periodically during 
subsequent visits through End of S tudy/E arly Termination.  
 
Objectives:  The primary objective of the study is to assess the safety  and tolerability  of 
an infusion dosing regimen of GRF6019  in subjects with  severe AD.  As a 
secondary objective, the study will assess the potential effects of GRF6019 on cognition  and function.  The exploratory objectives include serial 
compositional analysis of plasma proteins  to identify specific biomarkers 
associated with cognitive function and/or indicators of disease progression . 
 
Endpoints:  Primary E ndpoint (s):  
• Incidence of treatment-emergent AEs and SAEs identified by [CONTACT_6213] (PT) and grouped by [CONTACT_7204] (SOC)  
 Secondary Endpoint (s):  
• Changes in safety laboratory parameters  
• Changes in vital signs  
• Changes in body weight  

 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 10 of 69 
• Changes in physical exam  
• Changes in electrocardiogram (ECG) parameters  
• Changes in the Mini-Mental Status Examination  (MMSE) 
• Changes in the Severe Impairment Battery (SIB)  
• Changes in the Alzheimer’s Disease Cooperative Study Group 
Activities of Daily Living Inventory for Severe Alzheimer’s Disease 
(ADCS -ADL -Severe)  
• Changes in the Alzheimer’s Disease Cooperative Study – Clin ical 
Global Impression of Change  Caregiver Input  (ADCS -CGIC) 
• Change on the Neuropsychiatric Inventory (NPI) or NPI [INVESTIGATOR_124480]  (NPI -NH) 
 
Explorator y Endpoint (s): 
• Proteomic assessment of plasma for investigation of study -related 
biomarkers  
 
Population:  Approximately 20 subjects between 60 and 95 years of age with  severe AD .  
Assuming a drop -out rate of 2 0%, enrollment of 20 subjects  would yield 
approximately 16 evaluable subjects.  
 
Phase:  2  
 
Number of Sites:  Up to 4 sites in the [LOCATION_002] (US)  
Description  of Study 
Agent:  GRF6019: A  human plasma  protein fraction for IV infusion.  
 
Study Duration:  Approximately [ADDRESS_139967]  Duration:  Approximately 9 weeks  
  

 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 16 of 69 
4 STUDY DESIGN AND E NDPOINTS 
4.1 DESCRIPTION OF THE STUDY DESIGN  
 
This will be a prospective, randomized,  double -blind,  placebo -controlled study conducted at up to four  (4) sites in 
the [LOCATION_002].   
 During the Screening  Period , subjects will undergo all Screening assessments including  an echocardiogram.  
During the B aseline P eriod, subjects and their caregivers will complete a series of cognitive and functional  
assessments. 
 
Subjects that meet eligibility for inclusion in the trial will be randomized in a 2:1 ratio to  GRF6019 (Group 1) or 
placebo (Group 2).   Treatment groups will be stratified by [CONTACT_4321]. There will be one (1) dosing period during which 
subjects randomized to GRF6019 will receive GRF6019, while subjects randomized to placebo will receive placebo.  The dosing period consists of 5 consecutive days (“pulsed dosing”) of IV infusions of 250 mL of  either 
GRF6019 or placebo.  
 During the 5- day dosing period, subjects w ho do not already  reside in  a long-term care/skilled nursing facility  will 
be admitted  to such a facility  to facilitate safety evaluation .  Safety and tolerability assessments will occur at 
every visit.  Cognitive  and functional  assessments will be performed at Baseline and periodically at subsequent 
visits through End of Study/ Early Termination .  In the event of early termination of a subject  who has received at 
least one dose, the E nd of Study procedures will be performed unless the subject/subject’s legally authorized 
representative has withdrawn consent.  A comprehensive safety and efficacy assessment of all data in toto  will be 
conducted at the end of the study.  
 The overall duration of the study is approximately 12 months from study initiation (i.e., first subject enrolled) to 
study completion (i.e., last subject last visit).  The recruitment period is expected to be ap proximately [ADDRESS_139968] participation period is 9 weeks from S creening through End of S tudy, unless prematurely 
discontinued.  
 
4.2 STUDY ENDPOINTS  
 
4.2.1  PRIMARY ENDPOINTS  
 The primary endpoints pertain to safety and tolerability of the GRF6019 dosing regimen in subjects with  
severe AD.    The primary s afety endpoint  is as follows:  
• Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) identified 
by [CONTACT_124520] . 
 
Tolerability endpoint is  as follows:  
• Number of subjects completing [ADDRESS_139969] 5 infusions.  
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139970] statistically significant differences in cognitive  domains  between the 
baseline and e nd of s tudy values.  S econdary endpoints will be summarized over the study period from 
baseline values using descriptive statistics. 
 Secondary safety endpoints are as follows:  
• Changes from baseline in clinical laboratory parameters.  
• Changes from baseline in vital sign measurements . 
• Changes in body weight from b aseline to Visit 8.  
• Changes from baseline in physical exam parameters at  Visit 10  or End of Study/ Early Termination . 
• Changes from baseline in ECG recordings.  
 Secondary e fficacy e ndpoints  are as fol lows: 
• Changes in  the MMSE  (Folstein 1975,  Appendix 1
). 
• Changes in the SIB (Panisset 1994,  Appendix 2 ). 
• Changes in the  ADCS -ADL -Severe (Galasko 200 5, Appendix 3 ). 
• Changes in the ADCS -CGIC (Ferris 1997, Schneider 1997 , Appendix 4 ). 
• Change  on the NPI/NPI -NH (Cummings 1994, Wood 2000, Appendix 5 ). 
 
Secondary feasibility endpoints include:  
• Subject compliance with the study visit schedule, procedures, infusions, and any required adaptations 
that are necessary for study completion . 
• Success of blinding .  This  will be assessed based on all occurrences (intentional or unintentional) of 
unblinding of blinded study subjects  or study personnel (e.g.  investigators, medical providers , 
cognitive testing raters, the Sponsor or their representatives) .  
 
4.2.[ADDRESS_139971]’s plasma will be performed to identify 
specific biomarkers associated with cognitive functional changes and/or indicators of AD progression.  DNA 
will be extra cted from blood samples to explore epi[INVESTIGATOR_14364].   
 
[ADDRESS_139972] meet the following criteria:  
1. Male or female, aged 60-95 years (inclusive ). 
2. Diagnosi s of AD based upon the National Institute on Aging-Alzheimer’s Association (NIA-AA) 
Criteria. 
3. MMSE Score  0 – 10 (inclusive ). 
4. Modified Hachinski Ischemia Scale (MHIS) score of ≤ 4.  
5. If on medications for cognition (e.g., rivastigmine, galantamine, donepezil, memantine), must be on stable dosage for at least 8 weeks prior to Baseline.  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 18 of 69 
6. If on daily  antidepressant medications and/or  benzodiazepi[INVESTIGATOR_22199]/or typi[INVESTIGATOR_124481] s, must be on stable dosage for 8 weeks prior to Baseline. If on  prn dosing with atypi[INVESTIGATOR_124482]/or benzodiazepi[INVESTIGATOR_1651], these should not be given within 24 hours before each day of 
cognitive and other ratings  (V1, V2, V8, V9, V10) .  
7. The subject (with support of a caregiver and/or staff) must be able to follow the study protocol, receive 
the treatment in the established timeframe, and continue during the follow -up interval.   
8. The subject must be sufficiently fluent in English and have visual and auditory acuity sufficient to be capable of reliably completing all study assessments.  
9. Provided a signed and dated informed consent form (subject’s legal representative) in accordance with local regulations/guidelines/IRB.  
10. Adequate renal function as defined b y estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 
m
2 using the Modification of Diet in Renal Disease (MDRD) study equation  and no microal buminuria .  
11. Systolic ejection fraction of ≥ 55% on trans -thoracic echocardiogram.  
 
5.2 EXCLUSION CRITERIA  
 
An individual will not be eligible for inclusion if any of the following criteria apply : 
1. Evidence of clinically relevant neurological disorder(s) other than probable AD. 
2. History of coagulation disorders or hypercoagulability; any concurrent use of an antic oagulant therapy 
(e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors).  Use of antiplatelet drugs (e.g., aspi[INVESTIGATOR_87494]) is a llowed . 
3. Prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy.  
4. Treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to Screening.  
5. History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency .  
6. History o f anaphylaxis or thromboembolic  events as a complication of intravenous immunoglobulins.  
7. Unstable coronary h eart disease, e.g.  myocardial infarction  or severe or unstable  angina  in the 6 
months prior to dosing.  
8. Clinically significant abnormalities on echo cardiogram.  
9. Moderate to severe congestive heart failure ([LOCATION_001] Association Class III or IV) . 
10. Poorly controlled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood pressure of 100 mmHg or higher) despi[INVESTIGATOR_124483] 3 months prior to dosing, or treatment-refractory high blood pressure, defined as treatment requiring 3 or more antihypertensives from different classes.  
11. History of Torsades de Pointes dysrhythmia. 
12. Clinically significant abnormalities on screening  ECG including QTc intervals (using Fridericia’s 
correction formula) of ≥ 450 ms in men and ≥ 470 ms in women.  
13. History  of hypocalcemia of any kind, including secondary to absorption syndromes secondary to 
gastric by[CONTACT_4897].  
14. Clinically significant live r disease or biliary abnormalities.  
15. Uncontrolled diabetes defined as HbA1c >7.5%.  
16. Malignancy for which the subject  has undergone resection  and/or  radiation and/or chemotherapy in the  
past 3 years; treated basal cell carcinoma and/ or fully cured squamous cell carcinoma is  allowed . 
17. Clinically significant abnormalities in complete blood count, complete metabolic panel, serum albumin, blood coagulation tests, or the levels of thiamine, pyridoxine, cobalamin and thyroid 
stimulating horm one. 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 19 of 69 
18. Hemoglobin <10 g/dL in women and <11 g/dL in men.  
19. Urine protein -to-creatinine ratio (UPCR) of > 1.[ADDRESS_139973] 30 days for small molecules, and 1 year for active or passive immunotherapi[INVESTIGATOR_124484].  
22. Subjects who ha ve a level of agitation that , in the opi[INVESTIGATOR_871] , could interfere with 
study procedures . 
23. Any other condition and/or situation that the investigator believes may interfere with the safety of the subject, the intent and conduct of the study , or interpretation of study data.  
 
5.3 STRATEGIES FOR R ECRUITMENT AND RETENTION 
 
The Sponsor does  not anticipate any specific challenges in meeting recruitment goals of enrolling  and retaining a 
total of approximately 20  subjects in this study.  Subjects will be recruited continuously until the planned sample 
size is achieved.  Subjects who withdraw or are withdrawn during Screening, as well as subjects who discontinue, may be replaced  (see Section 5.4.2 Handling of Participant Withdrawals or Termination
).  
 
This trial is enrolling subjects with severe AD who have sufficient cognitive impairment to be considered a 
vulnerable population.  In this situation, consent will be obtained from  the legally authorized representative.  T he 
subject’s agreement to participate in the study will be obtained via an informed assent form and/or to their best 
level of his or her understanding .  Recruitment will not proceed if the subject refuses, shows significant distress, 
or the legally authorized representative refuses .   
 
The expected length of participation in the study, ~[ADDRESS_139974] will  be withdrawn from  the study for the following medical or administrative reasons:  
• Occurrence of an AE  that represents an unacceptable risk to the subject  and when continued 
participation in the investigational study is not warranted, in  the judgment of the investigator , 
Sponsor , or medical monitor .  The investigator must follow the subject until the AE re solves or is 
stable, unless the subject is lost to follow up . 
• Treatment with a prohibited concomitant medication other than the use of appropriate medications for the treatment of AEs under direction of the investigator . 
• Subject noncompliance, defined as r efusal or inability to adhere to the trial schedule or procedures. 
• At the request of the subject’s legally authorized representative (e.g., withdraws consent), 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 20 of 69 
investigator, Sponsor , or regulatory authority . 
• Pregnancy.  
 
5.4.2 HANDLING OF PARTI CPANT WITHDRAWALS OR TERMI NATION    
 
Subjects will be encouraged to complete the study and all assessments.  However, subjects may voluntarily 
withdraw at any time, and the investigator may discontinue individual subjects from the study at any time.    Approximat ely 20 subjects will be enrolled in the study with the intent of obtaining ~ [ADDRESS_139975]-study AE and  SAE reporting, see Section 8.3.1
.  The primary reason for study discontinuation will be 
documented on the case report form (CRF).  
 
5.4 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
 
The Sponsor  reserve s the right to terminate the study at any time.  Should this be necessary, the Sponsor and/or 
their representatives will arrange discontinuation procedures and notify the appropriate regulatory authority(ies)  
and IRBs.  In terminating the study, the Sponsor  and the investigator will continue to protect the subjects’ privacy 
and identity as required by [CONTACT_124521].  
 Alkahest, Inc. has the right to terminate a study site from participating in the study at any time. Reasons for study or site termination may include, but are not limited to: 
• (Immediate) risk to subject safety.  
• Unsatisfactory subject enrollment . 
• Unacceptable Protocol Deviations . 
• Inaccurate or incomplete data entry and recording; fabricated d ata. 
• Investigational site non-compliance with ICH/GCP . 
• Unacceptable emergent safety profile.  
6 STUDY AGENT 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION   
 
6.1.1  ACQUISITION  
 GRF6019 is  manufactured by [CONTACT_124522], Inc. (Clayton, North Carolina , US).  The placebo control 
agent will be 0.9% sodium chloride injection, USP (saline).  The study agent and placebo  will be supplied to 
the sites directly from a depot.  
 
 
6.1.2  FORMULATION, APPEARANCE, PACKAGING , AND LABELING  
 
 

 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139976] or other qualified personnel is 
responsible for ensuring adequate accountability of all used and unused study agent and placebo control agent.  This includes acknowledgment of receipt of each ship ment of study agent and placebo (quantity and condition), 
subject dispensing records, and returned or destroyed study agent/placebo.   Dispensing records will document 
quantities received and quantities dispensed to subjects including the date dispensed, in tended subject’s study 
identifier, initials of the individual responsible for dispensing, and  initials of the  Infusion Nurse administering the 
study agent.  Drug accountability will be monitored by [CONTACT_124523] .  
 Accountability records must be maintained and readily available for inspection by [CONTACT_124524], Inc. or their designee and are open to inspection by [CONTACT_108889].  The accounts of any study agent/placebo accidentally wasted or intentional ly disposed of must be maintained.  
 
The disposal of used, partially used, or wasted study agent/placebo must be performed in accordance with the 
institution’s drug disposal policy , or as directed by [CONTACT_2728] .  At study initiation, the clinical study monitor will 
evaluate the site’s standard operating procedure for study drug disposal/destruction in order to ensure that it complies with study requirements.  At the end of the study, following final drug reconciliation by [CONTACT_2037], the 
study site will be in structed by [CONTACT_124525]/placebo, including empty 
containers.   A copy of the institution’s drug disposal policy should be maintained or referenced in the 
investigator’s study file . A certificate of (study agent/pl acebo ) destruction must be provided to the Sponsor if 
destroyed on site.  
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 23 of 69 
7 STUDY PROCEDURES AND  SCHEDULE 
7.1 STUDY PROCEDURES/EVALUATIONS  
 
7.1.1  STUDY SPECIFIC PROCE DURES  
 [IP_ADDRESS]  Screening Procedures  
During Screening, the following will be performed:  
• Assessment of AD  
• MMSE  
• MHIS  
• Medical history  
• Demographics  
• Review of medications 
• Vital signs  
• Physical examination  
• 12-lead ECG 
• Echocardiogram  
• Blood and urine collection for laboratory evaluations  
 
Detailed descriptions of each of these procedures are provided  in the sections immediately following.  
Information pertaining to all study activities performed during Screening, and the sequence of events is 
provided in Section 7.3.1 Screening
. 
 
[IP_ADDRESS].1 Assessment of Alzheimer’s Disease  
Subjects will undergo an assessment for AD using NIA-AA criteria ( McKhann 2011 ).  Probable AD is 
diagnosed when the subject meets criteria for dementia per MMSE score (Refer to Section  [IP_ADDRESS].2 ) and in 
addition, has the following characteristics: 
• Insidious onset.  Symptoms have a gradual onset over months to years, not sudden over hours or 
days;  
• Clear -cut history of worsening of cognition by [CONTACT_124526]; and  
• The initial and most prominent cognitive deficits are evident on history and examination in one of the following categories:  
o Amnestic presentation: It is the most common syndromic presentation of AD.  The deficits should include impairment in learning and recall of recently learned information.  There should also be evidence of cognitive dysfunction in at least one other cognitive domain.   
o Nonamnestic presentations:  
1. Language presentation: The most prominent deficits are in word -finding, but 
deficits in other cognitive domains should be present.   
2. Visuospatial presentation: The most prominent deficits are in spatial cognition, including object agnosia, impaired face recognition, simultanagnosia, and alexia.  Deficits in other cognitive domains should be pre sent.   
3. Executive dysfunction: The most prominent deficits are impaired reasoning, judgment, and problem solving.  Deficits in other cognitive domains should be present.   
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 24 of 69 
The diagnosis of probable AD should not be applied when there is evidence of one or more of the following:  
• Substantial concomitant cerebrovascular disease, defined by a history of a stroke temporally related to the onset or worsening of cognitive impairment . 
• The presence of multiple or extensive infarcts or severe white matter hyperintensity burden  
• Core features of dementia with Lewy bodies other than dementia itself. 
• Prominent features of behavioral variant frontotemporal dementia . 
• Prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive aphasia. 
• Evidence for another concurrent, active neurological disease, or a non-neurological medical comorbidity or use of medication that could have a substantial effect on cognition.  
 
Previous radiologic imaging and/or assessment of AD cerebrospi[INVESTIGATOR_124485] , if 
available, to support the clinical diagnosis of AD.    
[IP_ADDRESS].2 Mini -Mental Status Examination  
The MMSE (Folstein 1975 , Appendix 1
) consists of the following 5 components: orientation to time and 
place (2 items), registration of 3 words (1 item), attention and calculation (1 item), recall of 3 words (1 item), 
and language (6 items).  The scores from the [ADDRESS_139977] has 1 missing item, the following algorithm will be used to compute the total score: Total score = [(total score from completed items) / (maximum total score for completed items)] x (maximum total score [=30] for all items in the scale).  The total score is then rounded to the next highest integer.   
 
If there is more than 1 missing item, the total score will be considered missing at that time point.  The MMSE 
total score can range from 0 to 30, with higher sc ores indicating better mental status.  Change scores will not 
be calculated for the individual items.    
[IP_ADDRESS].3 Modified Hachinski Ischemic Scale  
The MHIS ( Rosen 1980
) is an [ADDRESS_139978] a dementia of vascular etiology and thus are excluded from participating in the trial.  
 
[IP_ADDRESS].[ADDRESS_139979]’s caregiver(s) during Screening.  The medical history should focus on recent history, with an 
emphasis on the history of cognitive symptoms related to probable AD.  Additionally, the medical history 
should include:  
• Current /past illnesses and conditions . 
• Current symptoms  of any active medical condition . 
• Surgeries and procedures . 
• Allergies. 
• Family history  in biological parents, siblings, and offspring of AD, other dementias, or neurological 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 25 of 69 
disorders , if known.  
• Social history  (e.g. smoking, alcohol, illegal substances), if known. 
• Prior imaging , cerebrospi[INVESTIGATOR_124486], or other relevant diagnostic tests, including genetics,  
if available.  
 
[IP_ADDRESS].[ADDRESS_139980]’s education level, ethnicity, and race may be collected  at 
Screening  if available . 
 
[IP_ADDRESS].[ADDRESS_139981]’s current medications, including 
over-the-counter drugs, herbal supplements and/or vitamins, as well as those taken by [CONTACT_124527] 
12 months.  Assessment of eligibility should include a review of permitted and prohibited medications.  Any additions, discontinuation , or dosage changes in medication during the course of the study will be recorded. 
 
[IP_ADDRESS].7 Vital Signs  
Vital signs will include seated systolic and diastolic blood pressure (mmHg), heart rate (beats per minute 
[bpm]), respi[INVESTIGATOR_1487] (breaths per minute), and  body  temperature.  Vital signs should be measured after the 
subject has been seated for 5 minutes.  
 
[IP_ADDRESS].8 Physical Examination  
A complete physical examination will be performed to assess the following organ systems: skin, ears, nose, 
throat, head, eyes, lungs/chest, heart, abdomen, musculoskeletal,  extremities, neurologic , and lymphatic 
systems.  Height and weight will also be documented  as specified in Section 15  Schedule of Events
. 
 
[IP_ADDRESS].[ADDRESS_139982] 5 minutes in a supi[INVESTIGATOR_12251].  In some cases, it may be appropriate to repeat abnormal ECGs to rule out technical factors 
contributing to ECG artifacts or abnormality.  It is important that leads are placed in the same positions ea ch 
time for consistency.  The overall conclusion with the interpretation of the ECGs will be recorded on the appropriate CRF.  The interpretation of the ECGs will be recorded as normal, abnormal but not clinically 
significant (NCS), or abnormal and clinically significant (CS).  Corrected QTc intervals will be calculated 
using Fridericia’s correction formula.   
 
[IP_ADDRESS].[ADDRESS_139983]’s left ventricular (LV) 
systolic function to ensure the subject’s ejection fraction is ≥ 55% ( Gebhard 2012
).   
 
[IP_ADDRESS].1 1 Biological Specimen Collection  
Biological samples will be obtained, analyzed, and stored appropriately for future analysis.  Blood will be 
drawn by a qualified medical provider, and urine specimens will also be collected.  These samples may be 
used for re-testing, further evaluation of an AE and/or assessment, and follow -up of other exploratory 
endpoints.  The timing and frequency for specimen collection and laboratory evaluations to be performed are described in the study’s laboratory manual and in Section 15 Schedule of Events
.   
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 26 of 69 
Samples that remain after study testing is complet e will be stored in the event additional testing (e.g., further 
evaluation of an AE or assessment of effect) is required.  Samples will be stored in a deidentified coded form.   
Subjects  (or their legally authorized representatives) can opt out of storage of samples for future analysis.   
 [IP_ADDRESS]  Procedures to Assess Safety  
Subjects enrolled in the trial will be monitored closely to assess safety and tolerability of the study agent and 
intervention.  Study -specific procedures that will be used for this purpose are summarized below.  
Information regarding the timing and frequency of these procedures is provided in 
Section 7.3 Study 
Schedule .  
• Review of AEs 
• Review of medications 
• Vital signs  
• 12-Lead ECGs 
• Targeted physical exams  
• Weight  
• End of S tudy (or Early Termination) p hysical e xamination  
• Blood and urine collection for clinical l aboratory evaluations  
 
[IP_ADDRESS].1 Review of Adverse Events  
AEs will be reviewed, documented, and reported as required at each visit (from time of consent through E nd 
of Study) .  For definitions, guidance, and additional information regarding AEs, refer to Section 8 .   
 
[IP_ADDRESS].[ADDRESS_139984]’s current medications, including over -the-counter 
drugs, herbal supplements and/or vitamins, as well as those taken by [CONTACT_124528].  Changes to the subject’s list of medications should be reviewed and recorded.  Review of medications should occur at 
every visit.  
 
[IP_ADDRESS].3 Vital Signs  
Refer to Section [IP_ADDRESS].7
 for a description of vital s igns.  Vital s igns will be collected at every visit.  During 
infusions, vital signs will be colle cted according to the Infusion Administration Manual by [CONTACT_124529].    
 
[IP_ADDRESS].4 12-Lead ECG  
Refer to  Section [IP_ADDRESS].9  for information pertaining to 12-Lead ECGs.  
 
[IP_ADDRESS].5 Targeted Physical E xams  
During the dosing period, a targeted physical exam , including auscultation of the heart and lungs, an 
assessment of peripheral edema, and weight, will be performed per the Study Schedule (Section 7.3 ).  
 [IP_ADDRESS].6 Physical Exam ination 
Refer to Section [IP_ADDRESS].8
 for a description of the complete p hysical e xam.  The  complete  physical exam  will 
be performed at S creening and repeated at E nd of S tudy (or E arly Termination).   
 [IP_ADDRESS].7 Blood and Urine Collection for Laboratory Evaluations  
As described in Section [IP_ADDRESS].[ADDRESS_139985] blood and urine samples collected for clinical 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 27 of 69 
evaluation (Section 7.2.1 Clinical Laboratory Evaluations ).  Refer to Section 15 Schedule of Events  for timing 
and frequency of blood and urine collection for laboratory evaluations.   
 
[IP_ADDRESS] Procedure s to Assess Efficacy  
Cognitive function will be assessed u sing assessment scales administered by  [CONTACT_124530].   Raters must be 
certified, as appropriate.  The same rater  should be used for the duration of each subject’s participation unless 
a change in rater is unavoidable.  Additionally, for scales that require an informant (e.g., caregiver),  the 
informant  should be consistent  throughout the  duration of each subject’s participation unless a change is 
unavoidable.  Informants  must have frequent contact [CONTACT_1155] (defined as approximately 10 hours per 
week).  The following scales will be used during the course of this study:  
• MMSE  
• SIB 
• ADCS -ADL-Severe  
• ADCS -CGIC  
• NPI [INVESTIGATOR_124487] -NH 
 
Information regarding the timing and frequency of these procedures is provided in  7.3 Study Schedule . 
 
[IP_ADDRESS].1 Mini -Mental Status Examination   
Refer to Section [IP_ADDRESS].2  for information pertaining to the MMSE.  
 
[IP_ADDRESS].[ADDRESS_139986] answers, thus decreasing the need for language output.  There  are 57 items , and it takes 
approximately 20 minutes to complete.  The range of possible  scores is 0-133 (Panisset 1994 , Appendix 2 ). 
 
[IP_ADDRESS].3 Alzheimer’s Disease Cooperative Study Group Act ivities of Daily Living Inventory for Severe 
Alzheimer’s Disease   
The ADCS -ADL -Severe assesses the competence of patients with AD in performing basic activities of daily 
living.  The ADCS-AD L-Severe contains 19 items covering physical and mental functioning and 
independence in self-care (e.g. dressing, grooming, bathing, eating, walking, and toileting) .  For each ADL, 
an informant (e.g., caregiver ) is first asked if the patient attempted the activity during the past [ADDRESS_139987] accurate definition of the 
patient’s level of performance.  The scores range from 0 to 54,  with higher scores indicating less functional 
impairment ( Galasko 2005 , Appendix 3 ). 
 
[IP_ADDRESS].4 Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change  Caregiver Input  
The ADCS -CGIC is a systematic method for assessing clinically significant change in a clinical trial as 
viewed by [CONTACT_124531].  The ADCS -CGIC focuses on clinicians' 
observations of change in the subject's cognitive, functional, and behavioral performance since the beginning 
of a tr ial.  It relies on both direct examination of the subject and interview of informants (Ferris  1997 , 
Schneider 1997, Appendix 4 ).  
 
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 28 of 69 
 
[IP_ADDRESS].5 Neuropsychiatric Inventory or Neuropsychiatric Inventory – Nursing Home Version  
The NPI ( Cummings 1994 ) comprises 10 behavioral areas and 2 types of neurovegetative changes (12 
domains): delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, 
apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and nighttime behavior disorders, and appetite/eating changes.  Information is  gathered from caregivers familiar with the patient’s 
behavior.  To serve as an informant, the caregiver must have at least daily contact [CONTACT_10970]. Initial 
responses to each domain screening question are "Yes" (present) or "No" (absent).  If the response to the domain question is "No," the interviewer goes to the next question.  If "Yes," the interviewer proceeds to ask the informant a series of subquestions for that domain.  For each behavioral domain, there are 4 scores: frequency, severity, domain total score (frequency x severity), and occupational disruptiveness.  Thus, the NPI [INVESTIGATOR_124488], as well as total severity and distress scores reflecting the sum of individual domain scores  
 The NPI-NH was derived from the NPI ( Cummings 1994
) to evaluate the neuropsychiatric manifestations and 
psychopathology of  patients with AD and other  dementia s who reside in nursing homes, extended care 
facilities , or other long-term care settings.  The NPI -NH i s an interview-based scale designed to be 
administered to  an informed professional nursing home caregiver (as opposed to a family or home -based 
caregiver in the standard NPI) involved in the daily care of the  subject .  Generally, the NPI -NH is used to 
evaluate changes in subject behavior that have appeared during a given period ( Wood 2000, Appendix 5 ). 
 
7.2 LABORATORY PROCEDURES/EVALUATIONS  
 
7.2.1  CLINICAL LABORATORY EVALUATIONS  
 
Biological samples (e.g. whole blood, serum, urine , buccal swab ) will be collected for laboratory evaluations 
in accordance with the Schedule of Events (Section 15 ).  Clinical sample processing and laboratory 
evaluations will be conducted by [CONTACT_124532] (CLIA) facilities.  Refer to the study’s laboratory manual for complete information regarding all laboratory evaluations to be performed, sample  collection procedures, and related requirements.  
 
The investigator is responsible for determining and documenting if out of range laboratory values are 
clinically significant or not.  All clinically significant values will be recorded as AEs in the CRF an d followed 
until resolution, unless the subject is lost to follow up.  Once resolved, the appropriate CRF page(s) will be updated.  
 
7.2.2  OTHER ASSAYS OR PROC EDURES 
 [IP_ADDRESS]  Apolipoprotein E (ApoE) Genotype Testing   
ApoE genotype is a known risk factor for AD pathogenesis, with presence of the ApoE ε4 allele carrying increased risk.  This risk is further influenced by [CONTACT_654], sex, race, and ethnicity.  Thus, determining ApoE 
genotype at B aseline will allow for the assessment of possible differential effects of ApoE genotype on safety, 
treatment efficacy, and other exploratory measures.   
 [IP_ADDRESS]  Proteomic and Genetic Biobanking  
Blood and plasma will be collected from subjects at multiple timepoints throughout the trial for biobanking.  
For information regarding the timing and procedures for sample collection and related requirements, refer to 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 29 of 69 
the study’s laboratory manual and Section [ADDRESS_139988] overview of the proteins that are present in the plasma sample by [CONTACT_58833] 1000 -5000 analytes and allow generation of a proteomic signature.  From this 
signature, we hope to identify key proteins that are drivers of cognitive function and/or indicators of disease progression.  Blood samples will be retained for analysis of emergent genetic markers of disease.  By 
[CONTACT_124533], we seek to identify the biomarkers relevant to further optimizing treatment in AD.  For information regarding future use of stored samples , see Section 12.5 Future Use of Stored Specimens
. 
 
7.2.3  SPECIMEN PREPARATION, HANDLING, STORAGE,  AND SHIPPI[INVESTIGATOR_124489]’s laboratory manual for specim en preparation, handling, storage, and shippi[INVESTIGATOR_4585].   
 
7.3 STUDY SCHEDULE  
 
Visit windows (when noted) should be benchmarked relative to Visit [ADDRESS_139989], such that subjects 
complete the entire study by [CONTACT_2006] 33 ± 7 days .  Study visit procedures are listed in the recommended order in 
which they should be completed.   
 
7.3.1 SCREENING  
 Screening Visit  (Day -28 to -8)  
□ Obtain informed consent  from the subject’s legally authorized representative and informed assent from 
the subject, if applicable, prior to performing any study -related assessments.  
□ Assess for probable AD using NIA-AA criteria and administer the MMSE . 
□ Conduct the MHIS . 
□ Obtain  medi cal history to determine eligibility based on inclusion/exclusion criteria. 
□ Collect demographic information. 
□ Review subject’s current and prior medications . 
□ Collect vital signs, height, and weight.  
□ Perform the physical exam.  
□ Perform the 12-lead ECG.  
□ Collec t blood  and urine specimens for labs. 
□ Perform transthoracic echocardiogram.  
 
Note: The Screening Visit may be split to allow sufficient time to complete all required procedures.   AEs and 
concomitant medications should be recorded during split visits, if applicable.  
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 30 of 69 
7.3.2  BASELINE 
 Baseline Visit (Day s -7 to -1) 
□ Re-review Screening assessments for eligibility.  
□ Review AEs and concomitant medications.  
□ Collect v ital signs . 
□ Ensure the subject has had an opportunity to eat a meal or snack prior to administering cognitive and functional assessments. 
□ Administer  cognitive  and functional  assessments in the following order : 
1. SIB 
2. ADCS -ADL-Severe  
3. ADCS -CGIC  
4. NPI [INVESTIGATOR_124487] -NH 
 
7.3.[ADDRESS_139990] dose on Visit 3.  
 
7.3.4 TREATMENT 
 The treatment period includes a total of 5 infusions during Wee k 1.  It is anticipated that sites will infuse 
subjects with 5 doses over 5 days.  A “grace day” is allowed in the event of unanticipated safety or health  
concerns during the treatment period.  
 Visit s 3 -7 (Days 1-5)  
□ Perform the following procedures prior  to administering study treatment:  
o Review AEs and concomitant medications. 
o Obtain samples for proteomics/epi[INVESTIGATOR_7009]/biobanking; fasting samples preferred ( Visit  3 
Only ). 
o Obtain sample for ApoE genotype testing ( Visit 3 Only ). 
o Obtain pre -infusion safety laboratory samples and assess results prior to the next day’s 
infusion (Visits 4, 5, and 6 Only ). (When using an i -STAT Handheld Blood Analyzer, the 
blood sample(s) may be obtained on the same day as the infusion, provided that a ll pre -
infusion safety lab results are available and interpreted prior to the subject’s infusion start on Visits  5, 6, and 7.)  
o Collect urine for urinalysis ( Visit 6 Only ). 
o Measure and record the subject’s weight in kilograms.  
o Perform targeted physical exam  (i.e. auscultation of heart and lungs and assessment of 
peripheral edema) ( Visits 3, 5, and 7 O nly). 
o Perform 12 -lead ECG ( Visit s 3 and 5  Only ). 
o Collect pre -infusion vital signs .  
□ Administer study treatment and perform safety assessments per th e Infusion Administration Manual .   
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 31 of 69 
7.3.5 FOLLOW -UP VISITS  
 
Follow -up Visit 8 ( Day 6 + 3 days)  
□ Review AEs and concomitant medications.  
□ Collect the following:  
o Vital signs and subject’s weight in kilograms.  
o Blood and urine samples  for safety labs (fasting samples pref erred).  
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred).  
□ Perform 12-lead ECG.  
□ Ensure the subject has had an opportunity to eat a meal or snack prior to administering cognitive and 
functional assessments.  
□ Administer  cognitive  and functional  assessments in the following order :  
1. SIB 
2. ADCS -CGIC  
 
Follow -up Visit 9 (Day 1 2 ± 3 days)  
□ Review AEs and concomitant medications.  
□ Collect the following:  
o Vital signs and subject’s weight in kilograms.  
o Blood samples for safety labs (fasting samples preferred).  
□ Ensure the subject has had an opportunity to eat a meal  or snack  prior to administering cognitive and 
functional assessments. 
□ Administer  cognitive and functional assessment s in the following order :  
1. SIB 
2. ADCS -CGIC  
3. NPI [INVESTIGATOR_124487] -NH 
 
7.3.6 FINAL STUDY VISIT  
 Visit 10 , End of Study (Day 33  ± 7 days)  
□ Review AEs and concomitant medication s. 
□ Collect the following:  
o Vital signs and subject’s weight in kilograms . 
o Blood and urine samples for exit safety lab s (fasting samples preferred). 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred) . 
□ Perform the physical exam . 
□ Perform the 12-lead ECG.  
□ Ensure the subject has had an opportunity to eat a meal prior to administering the cognitive and functional assessments.  
□ Administer  cognitive  and functional  assessments in the following order : 
1. MMSE  
2. SIB 
3. ADCS -ADL-Severe  
4. ADCS -CGIC  
5. NPI [INVESTIGATOR_124487] -NH 
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_139991] one infusion  but is terminated or terminates from the study early, the site 
should try to perform all assessments scheduled at the E nd of S tudy Visit.   
 
7.3.8 SCHEDULE OF EVENTS TABLE 
 A tabular summary of all procedures by [CONTACT_124534] 1 5 Schedule of Events
. 
 
7.4 CONCOMITANT MEDICATIONS, TREATMENTS,  AND PROCEDURES  
 
All prescription, over -the-counter, and non-prescription medications (including herbal therapi[INVESTIGATOR_124490]) 
must be documented i n the source documents and CRFs.  All subjects should be maintained on the same 
medications at the same dosage and administration for treatment of AD throughout the entire study period, as medically feasible, with no introduction of new chronic therapi[INVESTIGATOR_014].  Any changes in medications should be documented with reason for change (e.g., AE, etc.). 
 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  
 
The following are prohibited:  
• Concurrent participation in any other therapeutic treatment trial.  If there was prior clinical trial participation, subject must have discontinued investigational agents for at least 30 days for small molecules, and 1 year for active or passive immunotherapi[INVESTIGATOR_124491] S creening.  
• Use of an  anticoagulant therapy  (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors).   Use 
of antiplatelet drugs (e.g., aspi[INVESTIGATOR_87494]) is  acceptable.  
• Any drugs of the interferon class.  
• Systemic corticosteroids (e.g., hydrocortisone, cortisone, betamethasone, prednisone, prednisolone, triamcinolone, dexamethasone, fludrocortisone) for longer than [ADDRESS_139992] is essential.  Any instances of unblinding 
will be managed as indicated in Section 10.6.3 Breaking the Study Blind/Subject Code.
 
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
 
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  
 Per 21 CFR 312.32(a) an AE  is any untoward (unfavorable, harmful, or pathologic) medical occurrence in a 
subject administered a medicinal (investigational) product even if the event does not necessarily have a causal 
relationship with this treatment.    
An AE can therefore be an y unfavorable and unintended sign (including an abnormal laboratory finding that 
is deemed clinically significant), symptom, or disease temporally associated with the use of a medicinal 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 33 of 69 
(investigational) product whether or not related to the medicinal (investigational) product .   
 
An AE does include any:  
• Exacerbation of a pre -existing illness . 
• Subjective or objective symptoms spontaneously offered by [CONTACT_29159]’s caregiver 
and/or observed by [CONTACT_7413] . 
• Increase in frequency or intensity of a pre-existing epi[INVESTIGATOR_3756]. 
• Condition detected or diagnosed after study drug administration even though it may have been 
present prior to the start of the study (unless it can be demonstrated by [CONTACT_124535]/time of Informed Consent) . 
• Continuous persistent disease or symptoms present at b aseline that worsen following the start of the 
study . 
• Symptoms associated with disease not previously reported by [CONTACT_423]/caregiver . 
• Untoward medical occurrences considered by [CONTACT_110190] -mandated 
procedures . 
• Abnormal assessments (e.g., change on physical examination, ECG findings), if they represent a 
clinically significant finding, that were not present at b aseline or worsened during the course of the 
study . 
• Laboratory test abnormalities, if they represent a clin ically significant finding, symptomatic or not, 
which were not present at b aseline or worsened during the course of the study . 
 
An AE DOES NOT include a/an:  
• Elective medical or surgical procedure (e.g., surgery, endoscopy, tooth extraction, transfusion) .  
• Pre-existing diseases or conditions present or detected at the start of the study that do not worsen . 
• Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_124492], social and/or convenience admissions) . 
• The disease or disorder being studied or sign or symptom associated with the disease or disorder unless more severe than expected for the subject’s condition . 
• Overdose of either study drug or concurrent medication without any signs or symptoms.  
• Symptom s associated with AD that are consistent with the subject’s usual clinical course unless the 
symptom(s) meet(s) the criteria for “serious.” 
• Pregnancy . 
 
8.1.2  DEFINITION OF SERIOUS ADVERSE EVEN TS (SAE)  
 
A serious adverse event (experience) or reaction is an  untoward medical occurrence that, at any dose , fulfills 
one or more of the following criteria:  
a. Results in death (i.e., the AE actually causes or leads to death).  
b. Is life-threatening . 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 34 of 69 
• An AE  is considered “life-threatening” if, in the view of either t he investigator or Sponsor, its 
occurrence places the patient or subject at immediate risk of death; it does not include AEs which, had it occurred in a more severe form, might have caused death . 
c. Results in inpatient hospi[INVESTIGATOR_17127] e xisting hospi[INVESTIGATOR_059]. 
• Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen during the study is not considered an AE . 
• Complications that occur during hospi[INVESTIGATOR_1084]; if a complication prolongs hospi[INVESTIGATOR_059], the event is an SAE . 
• “Inpatient” hospi[INVESTIGATOR_124493] a hospi[INVESTIGATOR_124494]; it does not include presentation at a casualty or emergency room unless the event meets the definition of an Important Medical Event (in the 
opi[INVESTIGATOR_12182]) . 
d. Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions . 
• The term ‘disability’ means a substantia l disruption of a person’s ability to conduct normal life 
functions; this definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, accidental trauma (i .e., sprained ankle) that may interfere or prevent everyday life functions but do not 
constitute a substantial disruption . 
e. Results in a congenital anomaly in the offspring of a subject who received drug.  
f. Results in an Important Medical Event .  Import ant Medical Events are events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_124495], based upon 
appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition; examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse . 
• Medical and scientific judgment should be used in deciding whether prompt reporting is 
appropriate in this situation . 
 
Note: if either the i nvestigator or the Sponsor believes that the event is serious, the event must be considered 
serious and evaluated for expedited reporting.   
 
Note: the terms “severe” and “serious” are not synonymous.  Severity (or intensity) refers to the grade of an 
AE.  “Serious” is a regulatory definition.    
 
8.[ADDRESS_139993] be assessed for its seriousness and severity .  Severity will 
be assessed by [CONTACT_1719] u sing the following definitions:  
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 36 of 69 
from other sources is unexpected.  The suspected adverse reactions listed in the Investigator’s Brochure (i.e., “expected”) are those observed with the investigational drug and for which a causal relati onship between the 
event and the drug is suspected or confirmed.  
 Sponsor assessment of expectedness and relationship to study drug/causality will determine the need for expedited reporting of AEs.  
 
8.3 TIME PERIOD/ FREQUENCY FOR EVENT ASSESSMENT/ FOLLOW -UP 
 
At every study visit, subjects will be assessed for AEs and SAEs.  After the subject/subject’s caregiver  has had an 
opportunity to spontaneously mention any problems, the investigator should inquire about AEs by [CONTACT_7939] a non-leading question such as the f ollowing:  
1. “How are you feeling?”  
2. “Have you had any changes since your last assessment/visit?”  
3. “Have you taken any new medicines since your last assessment/visit?” 
 
8.3.[ADDRESS_139994] completes the study (or has their last visit) that the investigator judges may be  reasonab ly 
related to study treatment or study participation.  
 
8.[ADDRESS_139995] be described as follows: the date of onset, date of resolution, severity (mild, moderate, severe), frequency of the event (single epi[INVESTIGATOR_1865], intermittent, continuous), action 
taken with study treatment (no action taken, treatment held, treatment discontinued), outcome, causality* 
(unre lated, possibly related, definitely related), and seriousness criteria.  Each AE or suspected adverse 
reaction must be recorded separately.  
 *Note: Causality assessment will be made only when the AE occurs after the subject has initiated at least one 
infus ion of the study agent.  An AE occurring before the subject’s exposure to study agent will always be 
labeled as “unrelated”.  
 Any AE occurring during the study must be documented in the subject’s medical records and as an AE in the 
CRF.  Any SAE occurring during the study must be documented in the subject’s medical records and as an 
SAE in the CRF. 
 A separate set of SAE pages should be used for each SAE.  However, if at the time of initial reporting, 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 37 of 69 
multiple SAEs are present that are temporally and/or clinically related, they may be reported on the same SAE page.  
 The investigator should attempt to establish a diagnosis of the event (that meets the definition of an AE or SAE) based on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis should be documented as the AE and/or SAE and not the individual signs or symptoms.  The diagnosis will become the 
basis for the verbatim term as reported by [CONTACT_941] i nvestiga tor.  If no diagnosis is known, and clinical signs and 
symptoms are not present, the abnormal finding should be recorded.  
 
In addition to the investigator’s own description of the AE s, each AE will be encoded according to the 
MedDRA.  
 The investigator will take all appropriate and necessary therapeutic measures required for resolution of the AE.  Any medication necessary for the treatment of an AE must be recorded on the concomitant medication 
CRF .   
 
The SAE pages of the CRF should be completed as thoroughly as possible and signed by [CONTACT_124536]/her designee before transmittal to the study Contract Research Organization (CRO).  It is very important 
that the investigator provide his/her assessment of causality to study drug as well as an applicable diagnosis at the time of the initial SAE report.  
8.4.2  SERIOUS ADVERSE EVENT REPORTING  
 [IP_ADDRESS]  Timeframes for Reporting SAEs 
 Under 21 CFR 312.32(c), the Sponsor is required to notify FDA and all participating investigators in a safety 
report of potentially serious risks from clinical trials [i.e., Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]RS) ], as soon as possible after the Sponsor receives the safety information and determines that the 
information qualifies for reporting:  
• No later than 7 calendar days for events that are life threatening (in the opi[INVESTIGATOR_124496]) or that involve Death as an outcome . 
• No later than 15 calendar days for all other S[LOCATION_003]RS . 
 
As such, prompt notification of the Sponsor , and/or the Sponsor’s representatives,  and promptly providing 
requested follow -up information regarding SAEs is essential so that ethical and regulatory responsibilities and 
legal obligations can be satisfied .  Investigators are responsible for reporting SAEs according to the following 
timefra mes:  
 
• All SAEs occurring during the study should be reported immediately.  
• The SAE Report Form and relevant source documents, if applicable, must be completed and emailed to [EMAIL_2477]
 within 24 hours of observation or learning of the event.  
• Follow -up information must be sent to the CRO within [ADDRESS_139996] to follow  up. 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 38 of 69 
[IP_ADDRESS] SAE Information to Report  
 All information available regarding an SAE must be submitted in the timeframes indicated.  At a minimum, SAE reports must contain the subject ID, the SAE  verbatim term, onset date, relationship to study 
drug/causality, and a brief narrative of the event .  Please note that relationship to study drug/causality as 
well as the reported verbatim term are very important and should be included in the initial report , as it 
may impact expedited regulatory reporting requirements for the event.   The date of SAE discovery by [CONTACT_124537].  
 The investigator m ust record all  relevant information regarding an AE/SAE in the applicable sections of the 
CRF.  It is not acceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical records in lieu of 
completion of the appropriate AE/SAE pages.  However, there may be instances when copi[INVESTIGATOR_124497]/or the Sponsor.  If medical records are submitted to the CRO then all subject personal identifiers must be completely and thoroughly redacted prior to subm ission.  
 A blank SAE Report Form and instructions for SAE reporting will be provided to the site and will be 
maintained in the investigator’s study file .  The SAE Report Form must be completed and emailed to 
[EMAIL_2477]  according to the timeframes specified in Section [IP_ADDRESS]
.  The SAE Report 
Form should include copi[INVESTIGATOR_124498], if applicable.   Reconciliation of any discrepancy 
noted during monitoring and amending the CRF is required.  
 
If new information about an SAE  is received or corrections to data are needed , the investigator should 
complete a new SAE Report F orm and check the “follow -up” box on the form.  This follow -up SAE Report 
Form should be submitted within 24 hours of learning of the information, especially if the new information concerns seriousness, relatedness, or the event term of an AE.  
 Sites acting under their local IRB should submit all applicable events, unanticipated problems, and safety 
reports to the site’s local IRB, if applicable.  All safety report ing deviations should also be submitted to their 
local IRB, if applicable. 
 
8.4.[ADDRESS_139997] (AESI):  
• Clinically -significant peripheral edema or pulmonary edema . 
• Reduced kidney function (eGFR <45 mL/min/1.73 m2). 
• Suspected transmission of blood- borne infect ious agents.  
 
AESIs occurring during the study should be reported within [ADDRESS_139998] be reported according to the timeframes specified in 
Section [IP_ADDRESS] . 
 
8.4.[ADDRESS_139999]’s 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140000](s) observed in the child must be reported as an 
SAE within 24 hours of the investigator or study personnel’s fir st knowledge.  
 
8.5 STUDY HALTING RULES  
 
If any of the following safety events occur, a Safety Evaluation Meeting (defined below) will be triggered:  
• Three or more SAEs in the same system/organ/class (SOC) that are assessed as possibly or definitely 
related to the study agent (see Section 8.2.2 Relationship to Study Agent ). 
• An overall pattern of symptomatic, clinical, or laboratory events associated with the s tudy agent that the 
Sponsor’s Program Physician or designee consider a serious potential safety concern (e.g., suspi[INVESTIGATOR_124499]).  
Events that are more likely related to the infusion procedure, such as infiltration or hematoma, will not be 
considered “drug related” and will not contribute to the count of definitely -related SAEs that would trigger a 
Safety Evaluation Meeting.  
 
Safety Evaluation Meeting 
 
If safety events of potential concern occur during the trial (i.e., 3 related events in the same SOC or a suspi[INVESTIGATOR_124499], as defined above) , a Safety Evaluation Meeting will be triggered,  and dosing may be temporarily 
halted based on the observations.  The Sponsor will inform investigators and the FDA in the event of any temporary halt in dosing at any time during the conduct of the study.  The purpose of the meeting is for investigators, the Sponsor , and the CRO Medical Monitor to discuss and evaluate the safety of the subjects using 
availab le aggregated safety data and without compromising study blinding, unless the Sponsor deems unblinding 
necessary for safety evaluation .   
 Attendants at the Safety Evaluation Meeting will include the Program Physician of Alkahest (or his/her designee), 
the CRO M edical Monitor , and available active investigators participating in the trial.  After sufficient data 
review, the Sponsor will choose one of the following courses of action:  
1. Continue dosing with no change to protocol.  
2. Halt dosing in all groups and st op the study.  
3. Continue with a modified protocol design and amend the protocol as appropriate.  
 
8.6 SAFETY OVERSIGHT 
 
Safety oversight will be provided by [CONTACT_1034]’s Program Physician or his or her designee  and the CRO’s 
medical monitor in concert with the site investigators.  There will be no formal Data Safety Monitoring Board 
(DSMB) established.  As needed, Safety Evaluation Meetings will be convened as described in Section 8.5  to 
monitor th e ongoing safety of the study.  The Sponsor’s Program Physician  or designee is the final authority for 
safety oversight in the study.  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140001] of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s). 
 
• Monitoring for this study will be performed by [CONTACT_941] s tudy CRO  in accordance with the Clinical Monitoring 
Plan (CMP) to ensure the safety of clinical subjects and the accuracy and completeness of study data.  
• The Sponsor  will be provided with copi[INVESTIGATOR_124500]. 
• Details of clinical site monitoring tasks and scope are documented in the study’s  CMP.  The CMP 
describes in detail who will conduct monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports.  
• Independent audits may be conducted by [CONTACT_124538]’s designee  to ensure monitoring 
practices are performed consistently across all participating sites and that monitors are following the CMP.  
 
10 STATISTICAL CONSIDE RATIONS  
10.1 STATISTICAL DESIGN MODEL AND ANALYTICAL PLANS  
 
A Statistical Analysis Plan (SAP) with analytical details and assumptions will be developed and finalized  before 
database lock and unblinding of the  study data.  
 
10.[ADDRESS_140002] 
secondary efficacy  endpoints will be primarily descriptive; within -subject changes from baseline for each dosing 
group and among-group differences will be evaluated.   
 
10.3 ANALYSIS DATASE TS 
 
Four analysis datasets are possible however, analyses may not necessarily be conducted with all four : 
 
• Intention-to-Treat (ITT) Dataset : all randomized  subject s. 
• Safety Dataset : all subjects who received at least one dose of the study agent.   
• Evaluable Dataset:   all subjects who receive at least 4 of the 5 planned doses.  
o Per Protocol Dataset:   a subset of the Evaluable Dataset. A detailed description of the reasons for 
exclusion from the Per Protocol population will be included in the St atistical Analysis Plan (SAP). 
 
The presentation  of baseline characteristics will be conducted on the ITT dataset.  All safety analyses will be 
performed for the Safety Dataset.  Analyses of the secondary endpoints will focus on the Evaluable and/or Per 
Protocol Datasets.  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 41 of 69 
10.4 DESCRIPTION OF STATISTICAL METHODS   
 
10.4.1 GENERAL APPROACH  
 
Using the Evaluable and/or Per Protocol Datasets, all secondary endpoints will be summarized serially over 
time using descriptive statistics to assess the within -subject changes and between -group differences.  Overall 
baseline and demographic data will be summarized using descriptive statistics; between -groups testing will 
be used to evaluate the effectiveness of the randomization in producing homogeneous pre -treatment group s.   
 
Subject dis position (e.g., the number of subjects randomized, completed, and discontinued) will be  
summarized , and medical history data will be listed.  Prior and concomitant medications taken from 
Screening and during the study will be categorized by [CONTACT_124539], listed and summarized by [CONTACT_11840].   
 Final analyses are not limited to the summaries described herein.  As noted above, analytical details and assumptions will be fully presented in the SAP.  
 
10.4.[ADDRESS_140003] significant changes in cognition , function, ADLs, etc. ; however, using 
available data from analysis of the secondary efficacy  endpoints, including changes in scores from baseline, 
descriptive summari es will be developed.  Of particular interest wil l be the within -subject changes from 
baseline and their distribution around a null value of zero and a comparison between  groups to evaluate any 
trends in differences between subjects randomized to active and placebo agents.    
10.4.4  ANALYSIS OF THE SECO NDARY SAFETY ENDPOINTS  
 Actual values and changes from baseline in clinical laboratory measurements, vital signs, and body weight 
will be assessed and summarized.  Abnormal lab or  vital sign  values will be determined and flagged in the 
listings.  Laboratory shift tables or graphics displaying the change (number of subjects) relative to the reference range from baseline to each study visit may also be presented for each test.  The investigator  should 
exercise his or her medical and scientific judgment in deciding and documenting whether an abnormal 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 42 of 69 
laboratory finding or other abnormal assessment is clinically significant.  
 For secondary safety endpoints that are continuous in nature  (e.g. clinical laboratory parameters, systolic and 
diastolic blood pressure, heart rate, respi[INVESTIGATOR_697], temperature, body weight) the mean, median, minimum, maximum, and standard deviation will be plotted over time.  
 
For secondary safety endpoints that are categorical in nature (e.g. physical exam or ECG abnormalities), the 
frequency counts and percentages will be presented as a descriptive summary . 
 
Per-subject extent of exposure will be listed.  
 
10.4.[ADDRESS_140004] retention  will be 
assessed .   
 
10.4.6  BASELINE DESC RIPTIVE STATISTICS  
 See Section 10. 4.1
. 
 
 
10.4.7  PLANNED INTERIM ANALYSES  
 
No interim analyses are planned.  If a Safety Evaluation Meeting is triggered (see Section 8.5 ), an ad hoc 
interim safety analysis will be performed.  If such an ad hoc interim analysis is conducted, the treatment 
assignment will remain masked , unless unblinding is deemed necessary by [CONTACT_124540] .   
 
10.4.8 ADDITIONAL SUBGROUP ANALYSES  
 Not applicable.  
 
10.4.9  MULTIPLE COMP ARISON/MULTIPLICITY  
 No adjustments for multiplicity will be employed.  
 
10.4.10  TABULATION O F INDIVIDUAL RESPONSE D ATA  
 This will be further defined in the SAP.  
 
10.4.11  EXPLORATORY ANALYSES  
 
Not applicable.  
 
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 44 of 69 
their representatives.  If unintentional unblinding occurs during the study, root cause analysis will be evaluated, and corrective actions implemented as appropriate. 
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE D ATA/DOCUMENTS  
 
Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH E6 R2 and regulatory and institutional requirements for the protection of confidentiality of subject s.  Each site 
will permit authorized r epresentatives of regulatory agencies, the IRB, the Sponsor, or the Sponsor’s 
representatives to examine (and when permitted by [CONTACT_1289], to copy) clinical records for the purposes of 
quality assurance reviews, audits, and evaluation of the study saf ety, progress, and data validity.   
 
Source data are all information,  original  records  of clinical  findings,  observations,  or other  activities in a clinical  
trial necessary for the reconstruction  and evaluation  of the trial.  Examples  of these  original documents and 
data records  include,  but are not limited  to, hospi[INVESTIGATOR_20112],  clinical  and office  charts, laboratory notes, 
memoran da, subject ’s memory aids or evaluation checklists, pharmacy dispensing records, recorded audio tapes of 
counseling sessions, recorded data from automated instruments, copi[INVESTIGATOR_124501], microfiches, photographic negatives,  microfilm  or magnetic media, x- rays,  and 
subject  files and records  kept at the pharmacy, at  the laboratories,  and medico -technical  departments  involved  in 
the clinical  trial.   
 It is not acceptable for the CRF to be the only record of a subject ’s participation in the study.  This is to 
ensur e that anyone who would access the subject’s  medical record has adequate knowledge that the subjec t is 
participating in a clinical trial .  Source document templates will be developed for this study.
 
 
12 ETHICS/PROTECTION O F HUMAN SUBJECTS  
12.[ADDRESS_140005] /subject’s legally authorized 
representative (such as advertisements,  information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by [CONTACT_124541].  Approval from the IRB must be obtained before starting the study and should be documented in a letter to the investigator specifying the protocol number, protocol version, documents reviewed, and date on which the committee met and granted the approval.   
 All changes to the consent form will be IRB approved; a determination will be made regarding whether previously c onsented subject s need to be re-consented.  
 Any modifications or amendment s to the protocol must also be submitted to the IRB for approval prior to 
implementation.  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 45 of 69 
12.3 INFORMED CONSENT PROCESS  
 
12.3.1 CONSENT /ASSENT AND OTHER INFORMATIONAL DOCUMENT S 
 Consent /assent  forms describing in detail the study intervention, study procedures, and risks are given to the 
subject and/or the subject’s legally authorized representative and written documentation of informed consent is required prior to performing any study -related procedures.  
 
12.3.[ADDRESS_140006] participating in this study or their legally authorized representative af ter adequate explanation of the aims, 
methods, objectives, and potential hazards of the study and prior to performing any study -related procedures.  
 Subjects and/or their legally authorized representatives should have the opportunity to discuss the study w ith 
family members or other advisors and be given adequate time to consider participation carefully.  Subjects or their legally authorized representatives may voluntarily withdraw consent at any time throughout the course 
of the study .  The rights and welfare of subject s will be protected by [CONTACT_124542] s 
participation in the study.  
 The investigator or designee must utilize an IRB -approved consent /assent  form that contains the elements 
required by [CONTACT_124543].  Each informed consent will be appropriately signed and dated by [CONTACT_423] (if appropriate) and/ or their 
legally authorized representative and the person obtaining consent.  A copy of the signed consent form  (and 
assent form if applicable) will be provided to the subject and/or their legally authorized representative.  By 
[CONTACT_124544], all parties agree they will complete the evaluations required by [CONTACT_1758], 
unless they withdraw voluntarily or are terminated from the study for any reason.  
 Investigators will be expected to maintain a screening log of all potential study candidat es that includes 
limited information about the potential candidate (e.g., date of screening).  
 All consented subjects will be assigned a unique study number.  This number will be used to identify the 
subject throughout the clinical study and must be used on all study documentation related to the study subject.  Once a number is assigned to a subject, that number will remain with that study subject and will not be reused.  
 
If an individual’s medical chart or results of diagnostic tests performed as part of an individual’s regular medical  care are going to be used  for screening, written  informed consent  must  be obtained prior to review  
of that information in accordance with the Health Insurance Portability and Accountability Act (HIPAA)
. 
 
12.[ADDRESS_140007] confidence.  No information concerning the study or the data will be 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140008] documents and records required to be maintained by [CONTACT_093], including 
but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study.  The clinical study site will permit the stud y monitor to access to such records.  
 
The investigator must assure that subjects’ anonymity will be strictly maintained and that their identities are protected from unauthorized parties.   Only subject initials and an identification code (i.e., not names) should be 
recorded on non-local lab samples, requisitions and any documents submitted to the CRO, Sponsor , and/or IRB.  
The investigator must keep a subject log showing codes, names, and a ddresses for all subjects screened and for all 
subjects enrolled in the trial.  The study subject ’s contact [CONTACT_124545].  At the end of the study, all records will continue to be kept in a secure location 
for as long a period as dictated by [CONTACT_46202].
 
 
12.[ADDRESS_140009] ’s (or the subject’s legally authorized representative’s)  approval and as approved by [CONTACT_50810] , 
de-identified biological samples may be stored at Alkahest , or designee,  for future use.  These samples could be 
used for research and to improve treatment.  Alkahest will also be provided with a code -link that will allow 
linking the biologica l sample s with the specific data from each subject, maintaining the masking of t he identity of 
the study subject .  Subjects/subject’s legally authorized representatives may choose whether the Sponsor can store 
and use samples for further research.  
 During the conduct of the study, an individual subject (or subject’s legally authorized representative)  can choose 
to withdraw consent to have biological s amples  stored for future research.  However, withdrawal of consent for  
storage of biological samples will not be po ssible after the study is completed.  
 When the study is completed, access to study data and/or samples will be managed by [CONTACT_124546], or designee.   In 
the event Alkahest transfers ownership to another commercial Sponsor , ownership of the samples may be 
transferred as well.   
  
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140010]  and substantiate the integrity of the data 
collected.  Source documents are filed at the investigator’s site.   Data entered in the CRFs that are transcribed 
from source documents must be consistent with the source documents or the discrepancies must be explained.  All 
source documents should be completed in a neat, legible manner to ensure accurate int erpretation of data.  Black 
or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  When making changes or corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION F LUID OR TAPE ON THE ORIGINAL.   The investigator may need  to request previous medical 
records or transfer records, depending on the trial; also , current  medical records must be available. 
 
For each subject who receives the study agent /placebo , the CRF must be completed in a timely manner.   The 
investigator will review and approve  the CRF for each study subject after all data have been entered, the CRFs 
have been source document verified, and all queries have been resolved.  This also applies to records for t hose 
subjects who fai l to complete the study.  If a s ubject withdraws from the study, the reason must be noted on the 
CRF.  If a subject is withdrawn from the study because of an AE, thorough efforts should be made to clearly document the outcome.  
 All dat a collection and recordkeepi[INVESTIGATOR_124502] s must be compliant  with applicable ICH GCP.  
 
13.1.1 INVESTIGATOR RESPONS IBILITIES 
 The investigator will comply with the protocol (which has been approved/given favorable opi[INVESTIGATOR_124503]), ICH GCP, and applicable regulatory requirements.  The investigator is ultimately responsible for the conduct 
of all aspects of the study at the stud y site and verifies by [CONTACT_124547] .  The term “investigator” as used in this protocol as well as in other study documents, refers to the 
investigator or authorized study personnel that the investigator has  designated to perform certain duties.  Sub -
investigators or other authorized study personnel are eligible to sign for the investigator, except where the investigator’s signature [CONTACT_1788].  
 
13.1.[ADDRESS_140011] of the study to be fully 
documented and the study data to be subsequently verified.  These documents should be classified into two separate categories (although not limited to) the following: (1) investigator’s study file, and (2) subject 
clinical source documents. 
 The investigator’s study file will contain the protocol/amendments, CRF, IRB approval with correspondence, informed consent s, drug records, staff curriculum vitae and authorization forms, and other appropriate 
documents and  study -specific manuals (e.g., lab manual). 
 Subject clinical source documents would include (although are not limited to) the following: subject 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 48 of 69 
hospi[INVESTIGATOR_307]/clinic records, physician’s and nurse’s notes, appointment book, origi nal laboratory reports, ECG, 
radiologic imaging, X -ray, pathology and special assessment reports, consultant letters, screening and 
enrollment log, etc.  
13.[ADDRESS_140012] been notified.  Before the investigator destroys any material related to the clinical 
study, he/she must obtain approval in writing from the Sponsor . 
 
The investigator should keep a file where the full name [CONTACT_124555] [ADDRESS_140013], the investigator, 
or the study site staff.  When deviations occur, corrective actions are to be developed by [CONTACT_3483].   These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section  5.1.1  
• 5.[ADDRESS_140014] the completeness, accuracy, and/or reliability of the study data or that may 
significantly affect the rights, safety , or wellbeing of study participants.   Major Protocol Deviations may 
result in data that are not deemed evaluable for the per protocol  analysis and/or may require that subject s 
are discontinued from the study.   
 
Minor Protocol Deviations  are departures from the approved protocol relating to the conduct of a study 
that does not affect the rights, safety , and/or wellbeing of study participants or the study outcomes or data 
quali ty.  Minor Protocol Deviations do not require review by [CONTACT_7195].  Minor Protocol 
Deviations would not generally preclude subject data from the per protocol  analysis population.  
 
All deviations will be logged and tracked at the site and study level .  Periodic review of Protocol Deviations will 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 49 of 69 
serve as an indicator of site performance.  
 It is the responsibility of the site to use continuous vigilance to identify and report deviations promptly to the study CRO and/or Sponsor.  All deviations must be addressed in study source documents.  Notification of Protocol Deviations must be sent to the local IRB per their guidelines.  The site investigator and applicable study 
staff are responsible for knowing and adhering to their IRB  requirements.  
 
13.4 PUBLICATION AND DATA SHARING POLICY  
 
In compliance with The International Committee of Medical Journal Editors (ICMJE) clinical trials registration policy and Section [ADDRESS_140015] of 2007, this study will be registered by [CONTACT_124548].gov, a public trials registry which is sponsor ed by [CONTACT_10418].  
 
Notwithstanding the Sponsor’s requirements for registration and data sharing in ClinicalTrials.gov, any formal 
presentation or publication of data collected as a direct or indirect result of this trial will be considered as a joint publication by [CONTACT_093](s) and the Sponsor.  In the case of multicenter studies, it is mandatory that the first publication be made based on the totality of data obtained from all centers, analyzed as stipulated in the protocol, and presented and interpreted as documented in the final Clinical Study Report.  The resulting publication will 
name [CONTACT_124556] j ournal.  Where it is not permitted for all investigators to 
be included as authors, the publication will name [CONTACT_124557].  
 
Individual investigators may publish data arising from their own subjects.  The investigator will provi de the 
Sponsor with copi[INVESTIGATOR_124504] (including abstracts and posters) at least 60 days in advance of submission.  This review is to permit the Sponsor to review the communication for accuracy (thus avoiding 
potential discrepancies with submi ssions to regulatory authorities), to verify that confidential information is not 
inadvertently divulged , to allow adequate input or supplementary information that 
may not have been available to the investigator, and to allow establishment of co -authorship.  
 
Investigators participating in multicenter studies must agree not to engage in presentations based on data gathered 
individually or by a subgroup of centers before publication of the first main publication, unless this has been 
agreed otherwise by [CONTACT_124549].  However, in the event that no publication of the overall results has been submitted after approval of the Clinical Study Report, investigators may publish results of one or more center’s subjects to the same review as outlined above.  The Sponsor will circulate proposed multicenter publications to all investigators for review. 
 
Data will be reviewed by [CONTACT_106126].  The study Sponsor will have 9 0 days  
to review all definitive publications, such as manuscripts and book chapters, and a minimum of 30 days to review all abstracts.  
  

 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140016] and will establish a 
mechanism for the ir management.  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
  
CONFIDENTIAL/PROPRIETARY                                                                                                     Page 51 of 69  
 
15 SCHEDULE OF EVENTS  
15.1 SCHEDULE OF EVENTS T ABLE  
 
 

 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 53 of 69  
 
16 REFERENCES  
16.1 PUBLISHED REFERENCES  
 
Alzheimer’s Association.  2018 Alzheimer's Disease Facts and F igures. Alzheimers Dement. 201 8;14(3):367-
429. 
 
 
 
 
 
 
 
Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21(2):101- 17. 
 Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, et al. Solvent-dependent precipi[INVESTIGATOR_124505]. Biochim Biophys Acta. 2002;1597:28-35.  
 Cummings JL, Mega M, Gray K, Rosenberg -Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric 
Inventory: comprehensive assessment of psychopathology in dementia. Neur ology. 1994;44:2308-2314.  
 Ferris SH, Mackell JA, Mohs R, Scheider LS, Galasko D, Whitehouse P, et al. A multicenter evaluation of new treatment efficacy instruments for Alzheimer’s disease clinical trials: overview and general results. Alz Dis Assoc Dis. 1997;11(Suppl 2):S1-S12.  
 Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;1 2(3):189 -198.  
 Food and Drug Administration (FDA), U.S. Department of Health and Human Services. Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. December, 2012.  
 
 
 
 Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Ferris D; Alzheimer's Disease Cooperative Study. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol 
Soc. 2005 Jul;11(4):446-4 53. 
 

 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140017] of age on left ventricular ejection fraction assessed by 
[CONTACT_124550]. Eur Heart J. 2012;33:1.  
 Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140(7):501-509.  
 Mayeux R. Early Alzheimer’s disease. N Engl J Med. 2010;362:2194-2201.  
 McKhann GM, Knopman, DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging -Alzheimer's 
Association workgroups on diagnostic gui delines for Alzheimer's disease. Alzheimers Dement. 2011 
May;7(3):[ADDRESS_140018] for Adults (Conventional Units) | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases Available at: https://www.niddk.nih.gov/health -information/communicat ion-
programs/nkdep/laboratory-evaluation/glomerular -filtration-rate-calculators/mdrd -adults -conventional -units . 
Accessed: 16th February 2018.  Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely deme nted patients. Arch Neurol. 1994 Jan;51(1):41–[ADDRESS_140019], Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementia. Arch Neurology. 1980;7:486-488.  
 
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg, B, et al. Validity and reliability of the Alzheimer’s Disease Cooper ative Study -Clinical Global Impression of Change. Alzheimers Dis Assoc 
Disord. 1997;11 (Suppl 2):S22-S52.  
 Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive  function. Nature. 2011;477:90-94.  
 Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014 Jun;20(6):659-663.  
 

 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 55 of 69  
 
Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, Schnelle JF. The use of the 
neuropsychiatric inventory in nursing home residents. Characterization and measurement.  Am J Geriatr 
Psychiatry. 2000 Winter;8(1):75 -83. 
 
16.2 UNPUBLISHED REFERENCES 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 56 of 69  
 
17 APPENDICES  
 
The cognitive and functional  assessments in this section and associated information are provided as EXAMPLES 
ONLY .  The actual assessments, related source documents, and instructions for administration and scoring are 
included in a r ater reference manual or equivalent . 
 Appendix 1. The Mini-Mental Status Examination  
 Instructions for Administration and Scoring  
 
Orientation (10 points):  
• Ask for the date.  Then specifically ask for parts omitted (e.g., “ Can you also tell me what season it is? ”).  One 
point for each correct answer.  
• Ask in turn, “ Can you tell me the name [CONTACT_124558] (town, county, etc.)? ” One point for each correct answer.  
 
Registration (3 points):  
• Say the names of three unrelated objects clearly and slowly, allowing approximately one second for each.  After 
you have said all three, ask the patient to repeat them.  The number of objects the  patient names correctly upon the 
first repetition determines the score (0 -3).  If the patient does not repeat all three objects the first time, continue 
saying the names until the patient is able to repeat all three items, up to six trials.  Record the nu mber of trials it takes 
for the patient to learn the words.  If the patient does not eventually learn all three, recall cannot be meaningfully tested.  
• After completing this task, tell the patient, “ Try to remember the words, as I will ask for them in a l ittle while.”  
 
Attention and Calculation (5 points):  
• Ask the patient to begin with [ADDRESS_140020] by [CONTACT_124551].  Stop after five subtractions (93, 86, 79, 72, 65).  Score the total number of correct answers.  
• If the patient cannot or will not perform the subtraction task, ask the patient to spell the word “world ” backwards.  
The score is the number of letters in correct order (e.g., dlrow=5, dlorw=3).  
 
Recall (3 points):  
• Ask the patient if he or she can recall the three words you previously asked him or her to remember.  Score the total 
number of correct answers (0 -3). 
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 57 of 69  
 
Language and Praxis (9 points):  
• Naming: Show the patient a wrist watch and ask the patient what it is.  Repeat with a pencil.  Score one point for 
each correct naming (0 -2). 
• Rep etition: Ask the patient to repeat the sentence after you ( “No ifs, ands, or buts. ”).  Allow only one trial.  Score 0 
or 1. 
• 3-Stage Command: Give the patient a pi[INVESTIGATOR_124506], “ Take this paper in your right hand, fold it in 
half, and put it  on the floor. ” Score one point for each part of the command correctly executed.  
• Reading: On a blank pi[INVESTIGATOR_124507], “ Close your eyes, ” in letters large enough for the patient to 
see clearly.  Ask the patient to read the sentence and d o what it says.  Score one point only if the patient actually 
closes his or her eyes.  This is not a test of memory, so you may prompt the patient to “ do what it says” after the 
patient reads the sentence.  
• Writing: Give the patient a blank pi[INVESTIGATOR_124508] a sentence for you.  Do not dictate a 
sentence; it should be written spontaneously.  The sentence must contain a subject and a verb and make sense.  Correct grammar and punctuation are not necessary.  
• Copying: Show the patient  the pi[INVESTIGATOR_124509].  All ten angles must be present and two must intersect to score one point.  Ignore tremor and rotation.  
 
Interpretation of the MMSE  
 
Method  Score  Interpretation  
Single Cutoff  <24 Abnormal  
Range  <21 
>25 Increased odds of dementia  
Decreased odds of dementia  
Education  21 
<23 
<24 Abnormal for 8th grade education  
Abnormal for high school education  
Abnormal for college education  
Severity  24-30 
18-23  
0-17 No cognitive impairment  
Mild cognitive impairment  
Severe cognitive impairment  
   
Reference:  
Folstein MF, Folstein SE, McHugh PR. “Mini- mental state. ” A practical method for grading the cognitive state of 
patients for the clinician. J Psychiatric Res. 1975;12(3):189 -198.  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140021] extensions of instruments used to assess mild to moderate dementia. 
These subscales include orientation, attention, language, praxi s, visuospatial perception, construction, memory, 
orient ation  to name , and social interaction . Language is further divided into several subcategories as listed below. 
There are 5 1 items and it takes approximately 20 minutes to complete.  The range of possible scores is 0 -100. 
The items in the SIB are composed o f single one -step commands. They are represented in conjunction with 
gestural cues and can be repeated a number of times to facilitate comprehension. Only one answer is timed (verbal 
fluency). Scoring gives credit to nonverbal and partially correct respons es. 
Domain  Items/Cues  
1. Orientation  • Name  
• Place (town)  
• Time (month and time of day)  
2. Attention  • Digit span  
• Counting to visual and auditory stimuli  
3. Language  • Auditory and reading comprehension  
• Verbal  fluency (food and months of the year ) 
• Naming from description, pi[INVESTIGATOR_124510], objects, colors, and 
forms 
• Repetition 
• Reading  
• Writing  
• Copying of written material  
4. Praxis  How to use a cup and a spoon  
5. Visuospatial  perception  Discrimination of color and forms  
6. Construction  Spontaneous drawing, copying, and tracing a figure  
7. Memory  Immediate, short - and long -term recall for examiner’s name, objects, 
colors, forms, and a short sentence  
8. Orientation to name  [CONTACT_124559]’s name [CONTACT_124560]  
9. Social interaction   Shaking hands an d following general directions  
 
Reference:  
Panisset M, Roudier M, Saxton J, Boller F. Severe Impairment Battery: a neuropsychological test for severely 
demeted patietns. Arch Neurol. 1994 ;51:41-45.  
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 59 of 69  
 
Appendix 3. Alzheimer’s Disease Cooperative Study Group Activities of Daily Living Inventory for Severe 
Alzheimer’s Disease (ADCS -ADL -Severe)  
 The ADCS -ADL -Severe assesses the competence of patients with AD in performing basic activities of daily living.  
The ADCS -ADL -Severe contains 19 items covering physical and mental functioning and independence in self -care 
(see listing below) .  For each ADL, an informant (e.g., caregiver) is first asked if the patient attempted the activity 
during the past [ADDRESS_140022] 
accurate definition of the patient’s level of performance.  The scores range from 0 to 54, with higher scores indicating less functional impairment. 
 
ADL  Point Range  
1. Walks  0-3 
2. Grooms  0-3 
3. Bathes  0-3 
4. Eats  0-3 
5. Dresses  0-4 
6. Toileting  0-3 
7. Turns faucet on  0-1 
8. Turns faucet off  0-1 
9. Turns lights on  0-1 
10. Turns lights out  0-1 
11. Finds belongings  0-3 
12. Disposes of litter  0-3 
13. Clears table  0-3 
14. Travels beyond home  0-4 
15. Conversation  0-3 
16. Watches TV  0-4 
17. Uses telephone  0-5 
18. Obtains beverage  0-3 
19. Can be left alone  0-3 
TOTAL  0-54 
  
Reference:  
Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Ferris D; Alzheimer's Disease Cooperative Study. Detailed 
assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc. 2005 Jul;11(4):446 -453.  
 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 60 of 69  
 
 Appendix 4. Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change Caregiver 
Input (ADCS -CGIC)  
 The ADCS -CGIC  evaluates the patient in five treatment domains: 1) cognition (immediate and delayed memory, 
praxis, attention, and executive function); 2) clinical global change; 3) activities of daily living; 4) behavioral 
symptoms (agitation and other noncognitive symptoms); 5) cognition in severely impaired patients.   
Instructions for Administration of the ADCS -CGIC  
The ADCS -CGIC  consists of two parts; Part I, the baseline evaluation (includes information from both the subject 
and informant); Part II, AD CS_CGIC forms for both subject and informant.  
The overall intent of the ADCS -CGIC  is to provide a reliable means to assess global change from baseline in a 
clinical trial.  It provides a semi structured format to enable clinicians to gather necessary clini cal information from 
both the patient and informant to make a global impression of change.  
Part I is used to record baseline information to serve as a reference for future ratings.  Part II is composed of two 
sections, a subject interview form and an infor mant interview form.  These forms are used to record information 
from separate interviews with both the subject and informant from which an impression of change score is made.  
Baseline Evaluation  
At baseline, the clinician interviews the patient and caregiver, recording onto Part I notes about baseline status for later reference.  At baseline only, clinical information about the subject from any source can be used.  The clinician indicates on a checklist the sources of information compi[INVESTIGATOR_124511].  
Parts I and II share a similar format for recording relevant clinical information.  The column headed “Area” identifies various areas that a clinician might consider while evaluating a patient for potential clinical change, including what might be expected to be assessed in performing an ordinary but brief comprehensive office interview to determine a subject’s baseline status and eligibility for a clinical trial.  The “Probes” column provides 
sample items that a clinician might find useful in assessing an area, and these are intended as guides for collecting 
relevant information.  The last column provides space for notes.  For the baseline form, there are separate spaces for notes taken from the informant and patient interviews.  
There is no specified amount of time to complete the baseline form.  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page [ADDRESS_140023]. 
After completing the interviews, the clinician records the clinical impression of change on a 7 -point Likert -type 
scale (from marked improvement to marked worsening).  The ADCS -CGIC is a rating of ch ange and not of 
severity.  The clinician may refer to the baseline data in Part I.  
The clinician, alone, must make decisions about change, without consulting other staff.  The clinician should avoid 
asking opi[INVESTIGATOR_124512], which may contaminate  the ratings, such as opi[INVESTIGATOR_124513].  At the beginning of the interview, the clinician may wish to caution the informant to refrain from mentioning this information.  
The time allotted for the subsequent ratings of ch ange is [ADDRESS_140024] or informa nt interview.  This 
time was chosen on the basis of the mean time reported by [CONTACT_124552].  
 
References:  
Ferris SH, Mackell JA, Mohs R, Scheider LS, Galasko D, Whitehouse P, et al. A multicenter evaluation of new 
treatment efficacy instruments for Alzheimer’s disease clinical trials: overview and general results. Alz Dis Assoc Dis. 1997;11(Suppl 2):S1- S12. 
Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg, B, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study -Clinical Global Impression of Change. Alzheimers Dis Assoc Disord . 
1997;11 (Suppl 2):S22-S52.  
   
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 62 of 69  
 
Appendix 5. Neuropsychiatric Inventory  and Neuro psychiatric Nursing Home Version  
 The NPI  [INVESTIGATOR_124514] a familial and/or professional caregivers (informant). The NPI -NH was 
developed for use with professional caregiver s (informants) in a nursing home setting as a questionnaire about 
patients for whom they care.  Each of the 12 NPI -NH domains contains a screening question that reflects cardinal 
symptoms of that domain.  Initial responses to each domain screening question  are "Yes" (present) or "No" 
(absent).  If the response to the domain question is "No", the interviewer goes to the next question.  If "Yes," the 
interviewer proceeds to ask the informant a series of subquestions for that domain.  For each behavioral domai n, 
there are 4 scores: frequency, severity, domain total score (frequency x severity), and caregiver distress 
(NPI)/ occupational disruptiveness  (NPI -NH).  Thus, the NPI [INVESTIGATOR_124515] -NH evaluate response to therapy and provide 
symptom severity and distress ratings for each symptom reported, a s well as total severity and distress scores 
reflecting the sum of individual domain scores .  It takes approximately 2 0-30 minutes to complete the interview.  
 
12 Domains/Screening Questions: NPI 
1. Delusions: Does the pa tient have beliefs you know are not true? For example , insisting that people are trying to 
harm him/her or steal from him/her? Has he/she said that family members are not who they say they are or that the house is not their home ?  
2. Hallucinations: Does t he patient  have hallucinations  such as seeing false visions or hearing imaginary voices? 
Does he/she see m to see , hear, or experience things that are not present?  
3. Agitation/Aggression: Does the patient  have periods when he/she refuses to cooperate or won’t let people help 
him/her? Is he/she hard to handle?  
4. Depression/Dysphoria: Does the patient  seem sad or depressed? Does he/she say that he/she is sad or 
depressed?  
5. Anxiety: Is the patient  very nervous, worried, or frightened for no apparent reason? Does he/she seem very 
tense or fidgety? Is the patient afraid to be apart from you? 
6. Elation/Euphoria: Does the patient  seem too cheerful or too happy for no reason?  
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 63 of 69  
 
7. Apathy/Indifference: Has the patient lost interest in the world around him/her? Has he/she lost interest in doing 
things or lack motivation for participating in new activities? Is he/she more difficult to engage in conversation or 
doing chores ? Is the patient apathetic or indifferent? 
8. Disinhibition: Does the patient seem to act  impulsively without thinking? Does he/she say or do things that are 
not usually said or done in public? Does he/she do things that are embarrassing to you or others? 
9. Irritability/Lability: Does the patient get irritated and easily  disturbed? Are his/her moods very changeable? Is 
he/she extremely impatient? 
10. Aberrant Motor Behavior: Does the patient pace, do things over and over such as opening closets or drawers, 
or repeatedly pi[INVESTIGATOR_124516]?  
11. Nighttime Behaviors (only gi ven to caregivers who work the night shift): Does the patient have difficulty 
sleepi[INVESTIGATOR_007] (do not count as present if the patient simply gets up once or twice per night only to go to the bathroom 
and falls back asleep immediately)? Is he/she up at night? Does he/she wander at night, get dressed , or disturb your 
sleep ? 
12. Appetite/Eating: Has he/she had any changes in appetite, weight, or eating habits (count as NA if the patient is 
incapacitated and has to be fed)? Has there been any change in the type of food he/she prefers?  
12 Domains/S creening  Questions : NPI-NH  
1. Delusions: Does the resident  have beliefs you know are no t true? For example , saying that people are trying to 
harm him/her or steal from him/her? Has he/she said that family members or staff are not who they say they are or 
that his/her spouse is having an affair? Has the resident had any other unusual beliefs?  
2. Hallucinations: Does the resident  have hallucinations – meaning, does he/she see, hear, or experience things 
that are not present?  
3. Agitation/Aggression: Does the resident  have  periods  when  he/she refuses to let people  help him/her?  Is he/she 
hard to handle?  Is he/she noisy or uncooperative?  Does the resident attempt to  hurt or hit others?  
4. Depression/Dysphoria: Does the resident  seem sad or say that he/she is depressed?  Does the resident cry at 
times?  
5. Anxiety: Is the  resident very nervous, worried, or frightened f or no reason? Does he/she seem very tense and 
unable to relax? Is the resident afraid to be apart from you or from others that he/she trusts? 
 
 
Protocol  ALK6019-202   V3.010JUL 2019  
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                   Page 64 of 69  
 
6. Elation/Euphoria: Does the resident seem too cheerful or too happy for no reason? I don’t mean normal 
happi[INVESTIGATOR_124517], for example, laughing at things that others do not find funny?  
7. Apathy/Indifference: Does the residen t sit quietly without paying attention to things going on around him/her? 
Has he/she lost interest in doing things or lack motivation for participating in activities? Is it difficult to involve the 
resident in conversation or in group activities? 
8. Disinhibition: Does the resident do or say things that are not usually done or said in public? Does he/she seem 
to act impulsively without thinking? Does  the resident say things that are insensitive or hurt people’s feelings? 
9. Irritability/Lability: Does the resident get easily irritated or disturbed?  Are his/her moods very changeable? Is 
he/she extremely impatient? 
10. Aberrant Motor Behavior: Does the resident have repetitive activities or “habits” that he/she performs over 
and over such as pacing, wheeling back and forth, pi[INVESTIGATOR_124518], or winding string? (Do not include simple 
tremors or tongue movements) . 
11. Nighttime Behaviors  (only given to caregivers who work the night shift) : Does the resident have difficulty 
sleepi[INVESTIGATOR_007] (do not count as present if the resident simply gets up once or twice per night only to go to the bathroom 
and falls back asleep immediately)? Is he/she awake at night? Does he/she wander at night, get dressed , or go into 
others’ room? 
12. Appetite/Eating: Does the resident have an extremely good or poor appetite, changes in weight, or unusual 
eating habits (not applicable if the resident is incap acitated and has to be fed)? Has there been any change in the 
type of food he/she prefers?  
 
References:  
Cummings JL, Mega M, Gray K, Rosenberg -Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric 
Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.  
Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, Schnelle JF. The use of the 
neuropsychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000 Winter;8(1):75- 83. 